Drug Development Series: Review:

Discovery and development of anticancer aptamers

Christopher R. Ireson and Lloyd R. Kelland
Mol Cancer Ther 2006 5: 2957-2962 doi: 10.1158/1535-7163.MCT-06-0172 [Abstract] [Full Text] [PDF]  

Review:

Spindle checkpoint function and cellular sensitivity to antimitotic drugs

Hiroshi Y. Yamada and Gary J. Gorbsky
Mol Cancer Ther 2006 5: 2963-2969 doi: 10.1158/1535-7163.MCT-06-0319 [Full Text] [PDF]  

Research Articles: Therapeutics, Targets, and Development:

Blockade of transforming growth factor-ß-activated kinase 1 activity enhances TRAIL-induced apoptosis through activation of a caspase cascade

Min-Kyung Choo, Noritaka Kawasaki, Pattama Singhirunnusorn, Keiichi Koizumi, Shintaro Sato, Shizuo Akira, Ikuo Saiki, and Hiroaki Sakurai
Mol Cancer Ther 2006 5: 2970-2976 doi: 10.1158/1535-7163.MCT-06-0379 [Abstract] [Full Text] [PDF]  

Enhancement of Apo2L/TRAIL-mediated cytotoxicity in esophageal cancer cells by cisplatin

Wilson S. Tsai, Wen-Shuz Yeow, Alex Chua, Rishindra M. Reddy, Duc M. Nguyen, David S. Schrump, and Dao M. Nguyen
Mol Cancer Ther 2006 5: 2977-2990 doi: 10.1158/1535-7163.MCT-05-0514 [Abstract] [Full Text] [PDF]  

Novel in vivo imaging shows up-regulation of death receptors by paclitaxel and correlates with enhanced antitumor effects of receptor agonist antibodies

Jing Gong, David Yang, Saady Kohanim, Robin Humphreys, Lyle Broemeling, and Razelle Kurzrock
Mol Cancer Ther 2006 5: 2991-3000Published Online First December 5, 2006. doi: 10.1158/1535-7163.MCT-06-0188 [Abstract] [Full Text] [PDF]  

In silico design, synthesis, and biological evaluation of radioiodinated quinazolinone derivatives for alkaline phosphatase–mediated cancer diagnosis and therapy

Kai Chen, Ketai Wang, Agop M. Kirichian, Ayman F. Al Aowad, Lakshmanan K. Iyer, S. James Adelstein, and Amin I. Kassis
Mol Cancer Ther 2006 5: 3001-3013 doi: 10.1158/1535-7163.MCT-06-0465 [Abstract] [Full Text] [PDF]  

Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib

Alan Serrels, Iain R.J. Macpherson, T.R. Jeffry Evans, Francis Y. Lee, Edwin A. Clark, Owen J. Sansom, Gabrielle H. Ashton, Margaret C. Frame, and Valerie G. Brunton
Mol Cancer Ther 2006 5: 3014-3022Published Online First December 5, 2006. doi: 10.1158/1535-7163.MCT-06-0382 [Abstract] [Full Text] [PDF]  

Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor–positive human breast cancer cells

Matthew H. Herynk, Amanda R. Beyer, Yukun Cui, Heidi Weiss, Elizabeth Anderson, Tim P. Green, and Suzanne A.W. Fuqua
Mol Cancer Ther 2006 5: 3023-3031 doi: 10.1158/1535-7163.MCT-06-0394 [Abstract] [Full Text] [PDF]  

Combination therapy with IFN- plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells

Angela Papageorgiou, Ashish Kamat, William F. Benedict, Colin Dinney, and David J. McConkey
Mol Cancer Ther 2006 5: 3032-3041 doi: 10.1158/1535-7163.MCT-05-0474 [Abstract] [Full Text] [PDF]  

Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2–positive breast cancer cells in a synergistic manner

Fatima Cardoso, Virginie Durbecq, Jean-François Laes, Bassam Badran, Laurence Lagneaux, Françoise Bex, Christine Desmedt, Karen Willard-Gallo, Jeffrey S. Ross, Arsène Burny, Martine Piccart, and Christos Sotiriou
Mol Cancer Ther 2006 5: 3042-3051Published Online First December 5, 2006. doi: 10.1158/1535-7163.MCT-06-0104 [Abstract] [Full Text] [PDF]  

Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib

Mark J. Williamson, Jonathan L. Blank, Frank J. Bruzzese, Yueying Cao, J. Scott Daniels, Lawrence R. Dick, Jason Labutti, Anne M. Mazzola, Ashok D. Patil, Corinne L. Reimer, Marjorie S. Solomon, Matthew Stirling, Yuan Tian, Christopher A. Tsu, Gabriel S. Weatherhead, Julie X. Zhang, and Mark Rolfe
Mol Cancer Ther 2006 5: 3052-3061 doi: 10.1158/1535-7163.MCT-06-0185 [Abstract] [Full Text] [PDF] Supplementary Material  

Glucocorticoid receptor transcriptional isoforms and resistance in multiple myeloma cells

Beatriz Sánchez-Vega, Nancy Krett, Steven T. Rosen, and Varsha Gandhi
Mol Cancer Ther 2006 5: 3062-3070 doi: 10.1158/1535-7163.MCT-06-0344 [Abstract] [Full Text] [PDF] Supplementary Material  

Inhibition of phosphatidylinositol-3-kinase and mitogen-activated protein kinase kinase 1/2 prevents melanoma development and promotes melanoma regression in the transgenic TPRas mouse model

Barbara Bedogni, Scott M. Welford, Andrea C. Kwan, James Ranger-Moore, Kathylynn Saboda, and Marianne Broome Powell
Mol Cancer Ther 2006 5: 3071-3077 doi: 10.1158/1535-7163.MCT-06-0269 [Abstract] [Full Text] [PDF]  

Association of insulin-like growth factor binding protein-3 expression with melanoma progression

Yaguang Xi, Go Nakajima, Tray Hamil, Oystein Fodstad, Adam Riker, and Jingfang Ju
Mol Cancer Ther 2006 5: 3078-3084 doi: 10.1158/1535-7163.MCT-06-0424 [Abstract] [Full Text] [PDF]  

Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells

Ju-Hee Lee, Jung-Hyun Park, Yeonjoo Jung, Jee-Hyun Kim, Hyun-Soon Jong, Tae-You Kim, and Yung-Jue Bang
Mol Cancer Ther 2006 5: 3085-3095 doi: 10.1158/1535-7163.MCT-06-0419 [Abstract] [Full Text] [PDF]  

Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells

Warren Fiskus, Michael Pranpat, Maria Balasis, Bryan Herger, Rekha Rao, Arul Chinnaiyan, Peter Atadja, and Kapil Bhalla
Mol Cancer Ther 2006 5: 3096-3104 doi: 10.1158/1535-7163.MCT-06-0418 [Abstract] [Full Text] [PDF]  

Growth inhibition and induction of apoptosis in acute myeloid leukemia cells by new indolinone derivatives targeting fibroblast growth factor, platelet-derived growth factor, and vascular endothelial growth factor receptors

Emma Kulimova, Elisabeth Oelmann, Guido Bisping, Joachim Kienast, Rolf M. Mesters, Joachim Schwäble, Frank Hilberg, Gerald J. Roth, Gerd Munzert, Martin Stefanic, Björn Steffen, Christian Brandts, Carsten Müller-Tidow, Astrid Kolkmeyer, Thomas Büchner, Hubert Serve, and Wolfgang E. Berdel
Mol Cancer Ther 2006 5: 3105-3112 doi: 10.1158/1535-7163.MCT-06-0323 [Abstract] [Full Text] [PDF]  

Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias

Zhihong Zeng, Ismael J. Samudio, Mark Munsell, Jing An, Ziwei Huang, Elihu Estey, Michael Andreeff, and Marina Konopleva
Mol Cancer Ther 2006 5: 3113-3121 doi: 10.1158/1535-7163.MCT-06-0228 [Abstract] [Full Text] [PDF]  

Direct targeting of _vß₃ integrin on tumor cells with a monoclonal antibody, Abegrin^TM

Kathy Mulgrew, Krista Kinneer, Xiao-Tao Yao, Beth K. Ward, Melissa M. Damschroder, Bill Walsh, Su-Yau Mao, Changshou Gao, Peter A. Kiener, Steve Coats, Michael S. Kinch, and David A. Tice
Mol Cancer Ther 2006 5: 3122-3129 doi: 10.1158/1535-7163.MCT-06-0356 [Abstract] [Full Text] [PDF]  

Terbinafine inhibits endothelial cell migration through suppression of the Rho-mediated pathway

Pei-Yin Ho, Wen-Bin Zhong, Yuan-Soon Ho, and Wen-Sen Lee
Mol Cancer Ther 2006 5: 3130-3138 doi: 10.1158/1535-7163.MCT-06-0457 [Abstract] [Full Text] [PDF]  

Topoisomerase II and tubulin inhibitors both induce the formation of apoptotic topoisomerase I cleavage complexes

Olivier Sordet, Abby Goldman, and Yves Pommier
Mol Cancer Ther 2006 5: 3139-3144 doi: 10.1158/1535-7163.MCT-06-0463 [Abstract] [Full Text] [PDF]  

The endothelial cytoskeleton as a target of electroporation-based therapies

Chryso Kanthou, Simona Kranjc, Gregor Sersa, Gill Tozer, Anze Zupanic, and Maja Cemazar
Mol Cancer Ther 2006 5: 3145-3152 doi: 10.1158/1535-7163.MCT-06-0410 [Abstract] [Full Text] [PDF]  

Fanconi anemia D2 protein confers chemoresistance in response to the anticancer agent, irofulven

Yutian Wang, Timothy Wiltshire, Jamie Senft, Sharon L. Wenger, Eddie Reed, and Weixin Wang
Mol Cancer Ther 2006 5: 3153-3161 doi: 10.1158/1535-7163.MCT-06-0427 [Abstract] [Full Text] [PDF]  

Interleukin-13 receptor–targeted nanovesicles are a potential therapy for glioblastoma multiforme

A.B. Madhankumar, Becky Slagle-Webb, Akiva Mintz, Jonas M. Sheehan, and James R. Connor
Mol Cancer Ther 2006 5: 3162-3169 doi: 10.1158/1535-7163.MCT-06-0480 [Abstract] [Full Text] [PDF]  

Chemosensitization of carcinoma cells using epithelial cell adhesion molecule–targeted liposomal antisense against bcl-2/bcl-xL

Sajid Hussain, Andreas Plückthun, Theresa M. Allen, and Uwe Zangemeister-Wittke
Mol Cancer Ther 2006 5: 3170-3180 doi: 10.1158/1535-7163.MCT-06-0412 [Abstract] [Full Text] [PDF]  

Bisphenol A facilitates bypass of androgen ablation therapy in prostate cancer

Yelena B. Wetherill, Janet K. Hess-Wilson, Clay E.S. Comstock, Supriya A. Shah, C. Ralph Buncher, Larry Sallans, Patrick A. Limbach, Sandy Schwemberger, George F. Babcock, and Karen E. Knudsen
Mol Cancer Ther 2006 5: 3181-3190 doi: 10.1158/1535-7163.MCT-06-0272 [Abstract] [Full Text] [PDF]  

Influence of small interfering RNA corresponding to ets homologous factor on senescence-associated modulation of prostate carcinogenesis

Chaehwa Park, Inkyoung Lee, and Won Ki Kang
Mol Cancer Ther 2006 5: 3191-3196 doi: 10.1158/1535-7163.MCT-06-0570 [Abstract] [Full Text] [PDF] Supplementary Material  

RNA interference–mediated simultaneous down-regulation of urokinase-type plasminogen activator receptor and cathepsin B induces caspase-8–mediated apoptosis in SNB19 human glioma cells

Christopher S. Gondi, Neelima Kandhukuri, Shakuntala Kondraganti, Meena Gujrati, William C. Olivero, Dzung H. Dinh, and Jasti S. Rao
Mol Cancer Ther 2006 5: 3197-3208 doi: 10.1158/1535-7163.MCT-05-0531 [Abstract] [Full Text] [PDF]  

Plumbagin induces G₂-M arrest and autophagy by inhibiting the AKT/mammalian target of rapamycin pathway in breast cancer cells

Po-Lin Kuo, Ya-Ling Hsu, and Chien-Yu Cho
Mol Cancer Ther 2006 5: 3209-3221 doi: 10.1158/1535-7163.MCT-06-0478 [Abstract] [Full Text] [PDF]  

Tautomycetin inhibits growth of colorectal cancer cells through p21^cip/WAF1 induction via the extracellular signal–regulated kinase pathway

Joon-Hee Lee, Jung-Soo Lee, Sung-Eun Kim, Byoung-San Moon, Yong-Chul Kim, Seung-Kyou Lee, Sang-Kyou Lee, and Kang-Yell Choi
Mol Cancer Ther 2006 5: 3222-3231 doi: 10.1158/1535-7163.MCT-06-0455 [Abstract] [Full Text] [PDF]  

The synthetic triterpenoid 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole blocks nuclear factor-B activation through direct inhibition of IB kinase ß

Mark M. Yore, Karen T. Liby, Tadashi Honda, Gordon W. Gribble, and Michael B. Sporn
Mol Cancer Ther 2006 5: 3232-3239Published Online First December 5, 2006. doi: 10.1158/1535-7163.MCT-06-0444 [Abstract] [Full Text] [PDF]  

Assessment of celecoxib pharmacodynamics in pancreatic cancer

Antonio Jimeno, Maria Luz Amador, Peter Kulesza, Xiaofei Wang, Belen Rubio-Viqueira, Xiangfeng Zhang, Audrey Chan, Jenna Wheelhouse, Hidekazu Kuramochi, Koji Tanaka, Kathleen Danenberg, Wells A. Messersmith, Virna Almuete, Ralph H. Hruban, Anirban Maitra, Charles J. Yeo, and Manuel Hidalgo
Mol Cancer Ther 2006 5: 3240-3247 doi: 10.1158/1535-7163.MCT-06-0565 [Abstract] [Full Text] [PDF]  

Therapeutic interactions between stathmin inhibition and chemotherapeutic agents in prostate cancer

Sucharita J. Mistry and George F. Atweh
Mol Cancer Ther 2006 5: 3248-3257 doi: 10.1158/1535-7163.MCT-06-0227 [Abstract] [Full Text] [PDF]  

Preclinical pharmacokinetics, tissue distribution, and antitumor activity of a folate-hapten conjugate–targeted immunotherapy in hapten-immunized mice

Yingjuan Lu, Le-Cun Xu, Nikki Parker, Elaine Westrick, Joseph A. Reddy, Marilynn Vetzel, Philip S. Low, and Christopher P. Leamon
Mol Cancer Ther 2006 5: 3258-3267 doi: 10.1158/1535-7163.MCT-06-0439 [Abstract] [Full Text] [PDF]  

Photodynamic therapy mediates the oxygen-independent activation of hypoxia-inducible factor 1

Soumya Mitra, Scott E. Cassar, David J. Niles, John A. Puskas, John G. Frelinger, and Thomas H. Foster
Mol Cancer Ther 2006 5: 3268-3274 doi: 10.1158/1535-7163.MCT-06-0421 [Abstract] [Full Text] [PDF]  

Apoptosis induced by selenomethionine and methioninase is superoxide mediated and p53 dependent in human prostate cancer cells

Rui Zhao, Frederick E. Domann, and Weixiong Zhong
Mol Cancer Ther 2006 5: 3275-3284 doi: 10.1158/1535-7163.MCT-06-0400 [Abstract] [Full Text] [PDF]  

Methyl-3-indolylacetate inhibits cancer cell invasion by targeting the MEK1/2-ERK1/2 signaling pathway

Siyuan Zhang, Zhi Li, Ximei Wu, Qing Huang, Han-Ming Shen, and Choon-Nam Ong
Mol Cancer Ther 2006 5: 3285-3293 doi: 10.1158/1535-7163.MCT-06-0240 [Abstract] [Full Text] [PDF] Supplementary Material  

Gallic acid causes inactivating phosphorylation of cdc25A/cdc25C-cdc2 via ATM-Chk2 activation, leading to cell cycle arrest, and induces apoptosis in human prostate carcinoma DU145 cells

Chapla Agarwal, Alpna Tyagi, and Rajesh Agarwal
Mol Cancer Ther 2006 5: 3294-3302 doi: 10.1158/1535-7163.MCT-06-0483 [Abstract] [Full Text] [PDF]  

Effects of the chemotherapeutic agent doxorubicin on the protein C anticoagulant pathway

Joel Woodley-Cook, Lucy Y.Y. Shin, Laura Swystun, Sonya Caruso, Suzanne Beaudin, and Patricia C. Liaw
Mol Cancer Ther 2006 5: 3303-3311 doi: 10.1158/1535-7163.MCT-06-0154 [Abstract] [Full Text] [PDF]  

Corrections:

Aurora kinase inhibitor

Mol Cancer Ther 2006 5: 3312 doi: 10.1158/1535-7163.MCT-5-12-COR1 [Full Text] [PDF]  

Circadian clock and therapeutic index

Mol Cancer Ther 2006 5: 3312 doi: 10.1158/1535-7163.MCT-5-12-COR2 [Full Text] [PDF]  

To see an article, click its [Full Text] link. To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button. To see one abstract at a time, click its [Abstract] link.